89bio shot up 6.14% Friday, trading between a high of $14.45 and a low of $13.0 per share. Yesterday the stock finished at $13.35 per share, compared to an average analyst target price of $25.13.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardiometabolic diseases. The small-cap pharmaceutical preparations company is based in the United States, and over the last twelve months it has returned a dividend yield of 0.0%. 89bio has trailing twelve months earnings per share (EPS) of -4.08, which at today's prices amounts to a price to earnings (P/E) ratio of -3.47.
Based on its expected future earnings growth, the company has a price to earnings growth (PEG) ratio of None. Usually a PEG ratio between zero and one indicates a potentially undervalued company.
ETNB has a revenue per share ratio of 0 and an enterprise value to revenue ratio of -, based on its total revenue of $None. The company's revenues have a year-on-year growth rate of 0.0%, compared to a YoY growth rate of 0.0% for its earnings.
Here's an overview of the company's gross margins in recent years: